NL177747C - PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS WITH ANTI-THROMBOSIS ACTION, AND PROCESS FOR PREPARING NŸ2-ARYLSULPHONYL-L-ARGININE DERIVATIVES USABLE FOR USE IN SUCH PREPARATIONS. - Google Patents

PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS WITH ANTI-THROMBOSIS ACTION, AND PROCESS FOR PREPARING NŸ2-ARYLSULPHONYL-L-ARGININE DERIVATIVES USABLE FOR USE IN SUCH PREPARATIONS.

Info

Publication number
NL177747C
NL177747C NLAANVRAGE7613660,A NL7613660A NL177747C NL 177747 C NL177747 C NL 177747C NL 7613660 A NL7613660 A NL 7613660A NL 177747 C NL177747 C NL 177747C
Authority
NL
Netherlands
Prior art keywords
preparing
preparations
arylsulphonyl
arginine derivatives
pharmaceutical preparations
Prior art date
Application number
NLAANVRAGE7613660,A
Other languages
Dutch (nl)
Other versions
NL7613660A (en
NL177747B (en
Original Assignee
Mitsubishi Chem Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/638,985 external-priority patent/US4055636A/en
Priority claimed from US05/646,522 external-priority patent/US4018915A/en
Priority claimed from US05/649,219 external-priority patent/US4018913A/en
Priority claimed from US05/653,217 external-priority patent/US4055651A/en
Priority claimed from US05/656,014 external-priority patent/US4041156A/en
Priority claimed from US05/656,870 external-priority patent/US4046876A/en
Priority claimed from JP3062176A external-priority patent/JPS52113919A/en
Priority claimed from US05/669,743 external-priority patent/US4070457A/en
Priority claimed from US05/707,536 external-priority patent/US4036955A/en
Priority claimed from US05/713,486 external-priority patent/US4073914A/en
Priority claimed from US05/723,474 external-priority patent/US4096255A/en
Priority claimed from US05/728,051 external-priority patent/US4104392A/en
Application filed by Mitsubishi Chem Ind filed Critical Mitsubishi Chem Ind
Publication of NL7613660A publication Critical patent/NL7613660A/en
Publication of NL177747B publication Critical patent/NL177747B/en
Publication of NL177747C publication Critical patent/NL177747C/en
Application granted granted Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/22—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one naphthalene or hydrogenated naphthalene ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
NLAANVRAGE7613660,A 1975-12-09 1976-12-08 PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS WITH ANTI-THROMBOSIS ACTION, AND PROCESS FOR PREPARING NŸ2-ARYLSULPHONYL-L-ARGININE DERIVATIVES USABLE FOR USE IN SUCH PREPARATIONS. NL177747C (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US05/638,985 US4055636A (en) 1974-11-08 1975-12-09 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/646,522 US4018915A (en) 1976-01-05 1976-01-05 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/649,219 US4018913A (en) 1976-01-14 1976-01-14 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/653,217 US4055651A (en) 1974-11-08 1976-01-28 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/656,014 US4041156A (en) 1974-11-08 1976-02-06 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/656,870 US4046876A (en) 1974-11-08 1976-02-10 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
JP3062176A JPS52113919A (en) 1976-03-19 1976-03-19 Preparation of tertiary alkylester of n-substituted amino acid or thei r acid salts
US05/669,743 US4070457A (en) 1974-11-08 1976-03-24 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/707,536 US4036955A (en) 1976-07-22 1976-07-22 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/713,486 US4073914A (en) 1974-11-08 1976-08-11 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/723,474 US4096255A (en) 1974-11-08 1976-09-14 N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US05/728,051 US4104392A (en) 1974-11-08 1976-09-30 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them

Publications (3)

Publication Number Publication Date
NL7613660A NL7613660A (en) 1977-06-13
NL177747B NL177747B (en) 1985-06-17
NL177747C true NL177747C (en) 1985-11-18

Family

ID=27583260

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7613660,A NL177747C (en) 1975-12-09 1976-12-08 PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS WITH ANTI-THROMBOSIS ACTION, AND PROCESS FOR PREPARING NŸ2-ARYLSULPHONYL-L-ARGININE DERIVATIVES USABLE FOR USE IN SUCH PREPARATIONS.

Country Status (12)

Country Link
BE (1) BE849196A (en)
CA (1) CA1102316A (en)
DD (1) DD128681A5 (en)
DE (1) DE2655636A1 (en)
DK (1) DK154289C (en)
FI (1) FI65240C (en)
FR (1) FR2334349A1 (en)
GR (1) GR63103B (en)
LU (1) LU76347A1 (en)
NL (1) NL177747C (en)
NO (1) NO145379C (en)
PT (1) PT65934B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8203887D0 (en) * 1982-06-23 1982-06-23 Kabivitrum Ab NEW TROMBIN INHIBITIVE ASSOCIATIONS
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1133648C (en) * 1997-07-31 2004-01-07 伊兰药品公司 Substituted phenylalanine-type compounds that inhibit VLA-4 mediated leukocyte adhesion
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
JP2002535314A (en) 1999-01-22 2002-10-22 エラン ファーマシューティカルズ，インコーポレイテッド Compounds inhibiting leukocyte adhesion mediated by VLA-4
CA2359112A1 (en) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
MXPA01007394A (en) * 1999-01-25 2002-04-09 Wyeth Corp Compounds which inhibit leukocyte adhesion mediated by vla-4.
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
NZ567270A (en) 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
CN101273035A (en) 2005-09-29 2008-09-24 伊兰制药公司 Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
EA017110B1 (en) 2006-02-27 2012-09-28 Элан Фамэсьютикэлс, Инк. PYRIMIDINYLSULFONAMIDE COMPOUNDS (VARIANTS), METHOD FOR PREPARING SAME (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A DISEASE MEDIATED BY α4 INTEGRIN, METHOD FOR REDUCING AND/OR PREVENTING AN INFLAMMATORY COMPONENT OF A DISEASE OR AN AUTOIMMUNE RESPONSE
MX2011011326A (en) 2009-04-27 2012-02-13 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL165652C (en) * 1973-08-13 1981-05-15 Mitsubishi Chem Ind METHOD FOR PREPARING AN ANTI-THROMBOSIS ACTION PREPARATION AND / OR BLOOD THROMBINE DIAGNOSTIC BASED ON L-ARGININE DERIVATIVES, THE PREPARED PREPARATION, THE PREPARED DIAGNOSTIC AND METHOD OF PREPARATION.

Also Published As

Publication number Publication date
DE2655636C2 (en) 1993-03-11
FI65240C (en) 1984-04-10
DK550576A (en) 1977-06-10
NO145379B (en) 1981-11-30
GR63103B (en) 1979-09-05
DD128681A5 (en) 1977-12-07
NO764186L (en) 1977-06-10
FR2334349A1 (en) 1977-07-08
CA1102316A (en) 1981-06-02
NO145379C (en) 1982-03-10
FR2334349B1 (en) 1983-07-22
BE849196A (en) 1977-06-08
FI65240B (en) 1983-12-30
PT65934A (en) 1977-01-01
LU76347A1 (en) 1977-06-24
NL7613660A (en) 1977-06-13
NL177747B (en) 1985-06-17
DK154289C (en) 1989-03-28
FI763528A (en) 1977-06-10
PT65934B (en) 1978-06-13
DE2655636A1 (en) 1977-06-23
DK154289B (en) 1988-10-31

Similar Documents

Publication Publication Date Title
NL177747C (en) PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS WITH ANTI-THROMBOSIS ACTION, AND PROCESS FOR PREPARING NŸ2-ARYLSULPHONYL-L-ARGININE DERIVATIVES USABLE FOR USE IN SUCH PREPARATIONS.
NL177405C (en) METHOD FOR PREPARING PHARMACEUTICAL PREPARATIONS AND METHOD FOR PREPARING MEDICINAL COMPOUNDS, SUITABLE FOR USE IN THESE PREPARATIONS.
NL174348B (en) METHOD FOR MANUFACTURING PHARMACEUTICAL PREPARATIONS AND METHOD FOR PREPARING COMPOUNDS SUITABLE FOR USE IN THE FOREGOING METHOD
NL181628C (en) PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS WITH PROSTAGLANDINE-LIKE ACTION, AND METHOD FOR PREPARING 9-ALFA, 11-ALFA, 15-ALFA-TRIHYDROXY-PROSTA-4,5,13-TRI-ACID DERIVATIVES, PREVIOUSLY USED
NL7809404A (en) THIAZOLIC DERIVATIVES AND THIAZOLIC DERIVATIVES CONTAINING PHARMACEUTICAL PREPARATIONS AND METHODS FOR PREPARING ONE AND OTHER.
NL7703898A (en) PROCESS FOR PREPARING 2-SUBSTITUTED TRANS-HEXAHYDROPYRIDOINDOLS, PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS USING THEREOF AND PREPARATIONS SO FORMED.
NL155045B (en) PROCESS FOR PREPARING ORGANOSILICUM PREPARATIONS AND FOR THE ANTI-ADHESIA LAYER IN OBJECTS USING THESE PREPARATIONS.
NL169076C (en) METHOD FOR PREPARING OR MANUFACTURING PHARMACOLOGICAL PREPARATIONS WITH ANALGETIC AND ANTIPYRETIC ACTION, AND METHOD FOR PREPARING MEDICINAL COMPOUNDS, SUITABLE FOR USE IN SUCH PREPARATIONS
NL167685C (en) METHOD FOR PREPARING OR MANUFACTURING PHARMACEUTICAL PREPARATIONS, AND METHOD FOR PREPARING ALKANOLAMINE DERIVATIVES SUITABLE FOR USE IN THIS PROCESS
NL177917B (en) PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS BASED ON 1-SUBSTITUTED PYRAZOLONE-5 DERIVATIVES, AND METHOD FOR PREPARING 1-SUBSTITUISED-PERSOZEDUZOLATED PYRAZOLATED PREPARATIONS.
NL7612937A (en) THIENAMYCINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS AND THE PROCESS FOR PREPARING THEM.
NL161451B (en) PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION AND PROCEDURE FOR PREPARING A COMPOUND, SUITABLE FOR USE IN THE PREPARATION OF THIS PREPARATION.
NL7501914A (en) PROCESS FOR THE PREPARATION OF CEPHALOSSPORINS AND THEIR USE AS PHARMACEUTICAL PREPARATIONS.
NL7612941A (en) THIENAMYCINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS AND THE PROCESS FOR PREPARING THEM.
NL7602391A (en) METHODS FOR PREPARING AND USING L-3- (3,4-DIHYDROXY-PHENYL) -2-METHYL-ALANINE -PEPTIDES.
NL188944C (en) METHOD FOR PREPARING OMEGA-AMINO-KOXYBENZENE DERIVATIVES AND METHOD FOR PREPARING PHARMACEUTICAL PREPARATIONS USING THEIR USE AS AN ACTIVE COMPOUND
NL184111C (en) PROCESS FOR PREPARING ANDROSTONE AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE.
NL7612939A (en) THIENAMYCINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS AND THE PROCESS FOR PREPARING THEM.
NL7612942A (en) THIENAMYCINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS AND THE PROCESS FOR PREPARING THEM.
NL7604894A (en) PROCEDURES FOR PREPARING AND USING CHINAZOLINE DERIVATIVES.
NL161154B (en) PROCESS FOR PREPARING A PHARMACEUTICAL PREPARATION CONTAINING A 4-OXAZOLINE-2-ON-DERIVATIVE, PREPARATION AND PROCEDURE FOR PREPARING A COMPOUND SUITABLE FOR USE IN THE SAID PROCESS.
NL7612940A (en) THIENAMYCINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS AND THE PROCESS FOR PREPARING THEM.
NL7600045A (en) PROCESS FOR PREPARING PHARMACEUTICAL PREPARATIONS.
NL174042B (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS BASED ON A 5-Substituted-5-FENYLALKYLBARBITUURZUURDERIVAAT, AND METHOD FOR PRODUCING 5-Substituted-5-FENYLALKYLBARBITUURZUURDERIVATEN, SUITABLE FOR USE IN SUCH PREPARATIONS.
NL175995C (en) METHOD FOR PREPARING ANTI-ALLERGIC MEDICINAL PRODUCTS AND THE ACTIVE SUBSTANCES SUITABLE THEREFOR.

Legal Events

Date Code Title Description
BB A search report has been drawn up
BC A request for examination has been filed
A85 Still pending on 85-01-01
TNT Modifications of names of proprietors of patents or applicants of examined patent applications

Owner name: MITSUBISHI KASEI CORPORATION

V1 Lapsed because of non-payment of the annual fee